
Yohei Kosugi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2068662/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synthesis of a Novel Series of Tricyclic Dihydrofuran Derivatives: Discovery of 8,9-Dihydrofuro[3,2- <i>c</i>]pyrazolo[1,5- <i>a</i>]pyridines as Melatonin Receptor (MT ₁ /MT ₂) Ligands. Journal of Medicinal Chemistry, 2011, 54, 4207-4218.	6.4	57
2	Direct Comparison of Total Clearance Prediction: Computational Machine Learning Model versus Bottom-Up Approach Using In Vitro Assay. Molecular Pharmaceutics, 2020, 17, 2299-2309.	4.6	33
3	Prediction of Oral Pharmacokinetics Using a Combination of In Silico Descriptors and In Vitro ADME Properties. Molecular Pharmaceutics, 2021, 18, 1071-1079.	4.6	30
4	Evaluation of cytochrome P450-mediated drug–drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica, 2012, 42, 127-138.	1.1	21
5	Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities. European Journal of Pharmaceutical Sciences, 2020, 142, 105119.	4.0	12
6	Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist. Journal of Medicinal Chemistry, 2021, 64, 3059-3074.	6.4	9
7	Species differences and substrate specificity of CYP3A heteroactivation by efavirenz. Xenobiotica, 2015, 45, 345-352.	1.1	8
8	Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug–drug interactions using physiologically based pharmacokinetic modelling approach. Xenobiotica, 2019, 49, 1251-1259.	1.1	7
9	Direct Comparison of the Prediction of the Unbound Brain-to-Plasma Partitioning Utilizing Machine Learning Approach and Mechanistic Neuropharmacokinetic Model. AAPS Journal, 2021, 23, 72.	4.4	7
10	Risk assessment of drug–drug interactions using hepatocytes suspended in serum during the drug discovery process. Xenobiotica, 2014, 44, 336-344.	1.1	5
11	Discovery of a Novel and Brain-Penetrant <i>O</i> -GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization. Journal of Medicinal Chemistry, 2021, 64,	6.4	4